A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities-Reference-Cited by-同舟云学术

A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities

Published:2016 Issue:5 Volume:14 Page:1727-1735
ISSN:1477-0520
Container-title:Organic & Biomolecular Chemistry
language:en
Short-container-title:Org. Biomol. Chem.

Author:

Yang Feifei¹²³⁴⁵,Peng Shihong¹²³⁴⁵,Li Yunqi¹²³⁴⁵,Su Liqiang¹²³⁴⁵,Peng Yangrui¹²³⁴⁵,Wu Jing¹²³⁴⁵,Chen Huang¹²³⁴⁵,Liu Mingyao¹²³⁴⁵,Yi Zhengfang¹²³⁴⁵,Chen Yihua¹²³⁴⁵

Affiliation:

1. Shanghai Key Laboratory of Regulatory Biology

2. The Institute of Biomedical Sciences and School of Life Sciences

3. East China Normal University

4. Shanghai

5. China

Abstract

A series of novel histone deacetylase (HDAC) inhibitors were designed, synthesized and evaluated based on the strategies of a hybrid of the classic pharmacophore of HDAC inhibitors with the thiazolidinone scaffold.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2016/OB/C5OB02250A

Reference48 articles.

1. Targeting bromodomains: epigenetic readers of lysine acetylation

2. The Inheritance of Epigenetic Defects

3. Acetyltransferases (HATs) as Targets for Neurological Therapeutics